Аналитики считают CG Oncology более перспективной компанией, чем Immunovant, по большинству ключевых финансовых показателей

Immunovant (NASDAQ:IMVT – Get Free Report) and CG Oncology (NASDAQ:CGON – Get Free Report) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk. Institutional and Insider Ownership 47.1% of Immunovant shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Earnings and Valuation This table compares Immunovant and CG Oncology”s top-line revenue, earnings per share and valuation. CG Oncology has higher revenue and earnings than Immunovant. CG Oncology is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Risk and Volatility Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Profitability This table compares Immunovant and CG Oncology’s net margins, return on equity and return on assets. Analyst Ratings This is a breakdown of current recommendations for Immunovant and CG Oncology, as provided by MarketBeat. Immunovant presently has a consensus price target of $39.70, suggesting a potential downside of 0.45%. CG Oncology has a consensus price target of $81.73, suggesting a potential upside of 11.96%. Given CG Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe CG Oncology is more favorable than Immunovant. Summary CG Oncology beats Immunovant on 9 of the 12 factors compared between the two stocks. About Immunovant Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. About CG Oncology CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California. Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.